Fmr LLC Trims Holdings in Phreesia, Inc. (NYSE:PHR)

Fmr LLC reduced its holdings in shares of Phreesia, Inc. (NYSE:PHR) by 0.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,697,395 shares of the company’s stock after selling 44,054 shares during the period. Fmr LLC owned 11.59% of Phreesia worth $152,634,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of PHR. Deerfield Management Company L.P. Series C bought a new position in shares of Phreesia during the second quarter valued at $4,078,000. Champlain Investment Partners LLC increased its stake in Phreesia by 4.1% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock valued at $57,062,000 after purchasing an additional 97,847 shares in the last quarter. Sei Investments Co. raised its holdings in Phreesia by 135.3% in the second quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock worth $3,505,000 after buying an additional 95,058 shares during the last quarter. Squarepoint Ops LLC lifted its stake in shares of Phreesia by 56.3% in the second quarter. Squarepoint Ops LLC now owns 250,396 shares of the company’s stock worth $5,308,000 after buying an additional 90,215 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Phreesia during the third quarter valued at approximately $954,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Insider Activity

In related news, SVP David Linetsky sold 1,716 shares of Phreesia stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total transaction of $39,897.00. Following the transaction, the senior vice president now owns 203,318 shares in the company, valued at approximately $4,727,143.50. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Chaim Indig sold 5,295 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total value of $123,108.75. Following the completion of the sale, the chief executive officer now owns 1,223,736 shares of the company’s stock, valued at $28,451,862. The trade was a 0.43 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 29,997 shares of company stock valued at $667,943 in the last ninety days. Corporate insiders own 5.80% of the company’s stock.

Phreesia Trading Down 0.9 %

Shares of PHR stock opened at $20.92 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.77 and a quick ratio of 1.77. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -11.62 and a beta of 0.98. Phreesia, Inc. has a 1 year low of $14.55 and a 1 year high of $29.16. The firm has a fifty day moving average price of $20.35 and a 200-day moving average price of $21.80.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Wednesday, September 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.06. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. The business had revenue of $102.12 million during the quarter, compared to analyst estimates of $101.76 million. As a group, equities analysts predict that Phreesia, Inc. will post -1.23 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on PHR shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Phreesia in a research report on Thursday, September 5th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $23.00 price objective on shares of Phreesia in a research report on Friday, September 27th. Robert W. Baird boosted their target price on Phreesia from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Friday, September 6th. DA Davidson restated a “buy” rating and set a $32.00 target price on shares of Phreesia in a research note on Thursday, September 5th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Monday, September 9th. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $29.42.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.